{'Year': '2016', 'Month': 'Oct'}
Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.
Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti-TNF) has revolutionized the care of patients with inflammatory bowel disease (IBD).